Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC) saw a large drop in short interest in September. As of September 30th, there was short interest totalling 289,300 shares, a drop of 28.2% from the September 15th total of 403,000 shares. Based on an average daily volume of 418,000 shares, the short-interest ratio is currently 0.7 days.

Analysts Set New Price Targets

Separately, Leerink Partners decreased their target price on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th.

Hedge Funds Weigh In On Vincerx Pharma

Several hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP boosted its holdings in Vincerx Pharma by 359.1% during the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock worth $266,000 after buying an additional 256,967 shares during the last quarter. Vanguard Group Inc. boosted its stake in Vincerx Pharma by 29.9% in the 1st quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock worth $3,375,000 after purchasing an additional 153,575 shares during the period. Finally, Armistice Capital LLC bought a new stake in Vincerx Pharma in the 2nd quarter valued at approximately $1,610,000. Institutional investors own 44.02% of the company’s stock.

Vincerx Pharma Stock Performance

Shares of Vincerx Pharma stock remained flat at $0.39 on Friday. 590,714 shares of the stock were exchanged, compared to its average volume of 724,468. The company has a market capitalization of $11.63 million, a PE ratio of -0.30 and a beta of 1.49. The business has a fifty day moving average price of $0.67 and a 200-day moving average price of $1.03. Vincerx Pharma has a twelve month low of $0.38 and a twelve month high of $9.37.

Vincerx Pharma (NASDAQ:VINC) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.12. On average, sell-side analysts forecast that Vincerx Pharma will post -0.38 earnings per share for the current year.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.